Genprex appoints Dr. William Gannonn VP of Regulatory Affairs
Gene therapy company Genprex, Inc. has hired Dr. William Gannon as its Vice President of Regulatory Affairs. Dr. Gannon will manage the business's regulatory affairs for its clinical trials, liaise with trial personnel and assist with FDA communication throughout the trial process as Medical Monitor. “We are pleased to have Dr. Gannon join our team. His extensive experience in the management of clinical trials, from designing trials to building operational teams, will be an important asset for us as we work toward initiating our upcoming trials and seeing them through to successful completion,” said Genprex Chairman and Chief Executive officer Rodney Varner. Dr. Gannon has more than 30 years of expertise in clinical development, regulatory affairs and commercialization of products in biotechnology and pharmaceutical industries. He comes to Genprex from Capital City Technical Consulting, where he served as Chief Scientific Officer and Medical Director.